Recent Advances in Biomaterials for Immunotherapeutic Applications

A promising method for treating cancer, autoimmune disorders, and infectious diseases is immunotherapy. The creation of efficient biomaterials to deliver and boost the activity of immunotherapeutic drugs, however, is a key factor in the clinical success of immunotherapy. New chances to design immunotherapeutic platforms with increased efficacy and safety have been made possible by recent advancements in biomaterials. These biomaterials can control immune cell activity, exert enzyme-like action, neutralise cytokines, and cure inflammation, malignancies, autoimmune illnesses, etc. The utilisation of nanoparticle-based delivery systems designed immune cell treatments, and scaffold materials for immune tissue engineering are a few important advancements. The precise targeting of immune cells and the regulated delivery of immunotherapeutic drugs are both possible with nanoparticle engineering. Biomaterials are used in engineered immune cell therapies, such as CAR-T cells, to increase the persistence and effectiveness of immune cells. Scaffold materials can be utilised to create immunological tissues and support immune cell growth and function. These biomaterials can improve clinical outcomes of immunotherapeutic drugs by increasing their potency, specificity, and durability. Biomaterials for immunotherapeutic applications are developing quickly and show significant promise for the immunotherapy field’s future. This chapter discusses current developments in biomaterials for immunotherapeutic uses and their prospective effects on immunotherapy in the future.